SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Uniquity Bio Announces Statistically Significant and Clinically Meaningful Positive Topline Phase 2 Results for Solrikitug in Eosinophilic E

Solrikitug achieved placebo-corrected histologic remission rates of 69%—76% across all doses tested

Related stories